Of note, CLIP4 was associated with better OS in Luminal B and HER2 positive breast cancers but not TNBC type in this study, the result revealed that CLIP4 may be used as a target to overcome the drug resistance, incomplete responders, and relapsed in individualized treatment of Luminal B and HER2 breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.